|
| 37935879 | Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2024 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 37490155 | Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer. | Curr Cardiol Rep | 2023 |
| 37193610 | Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. | Clin Genitourin Cancer | 2023 |
| 36980557 | Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. | Cancers (Basel) | 2023 |
| 37277275 | Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. | Eur Urol | 2023 |
| 37467458 | Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers. | JCO Precis Oncol | 2023 |
| 36968334 | Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma. | Clin Med Insights Oncol | 2023 |
| 36996380 | Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). | J Clin Oncol | 2023 |
| 36795891 | Rucaparib or Physician's Choice in Metastatic Prostate Cancer. | N Engl J Med | 2023 |
| 36416812 | Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. | JAMA Oncol | 2023 |
| 36862387 | First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. | JAMA Oncol | 2023 |
| 36630480 | Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. | Sci Transl Med | 2023 |
| 36243543 | Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. | Eur Urol | 2023 |
| 34172290 | Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. | Mayo Clin Proc | 2022 |
| 35652618 | The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. | Prostate | 2022 |
| 35538398 | Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. | Prostate | 2022 |
| 35537621 | Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. | Crit Rev Oncol Hematol | 2022 |
| 35747193 | Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. | EClinicalMedicine | 2022 |
| 35483426 | Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. | Am J Med | 2022 |
| 36509074 | NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. | J Natl Compr Canc Netw | 2022 |
| 36212187 | Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. | Prostate Cancer | 2022 |
| 36135372 | Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. | Mol Cancer Res | 2022 |
| 35878715 | Radiation Therapy in Oligometastatic Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 35288936 | Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer. | Clin Pharmacol Ther | 2022 |
| 35210863 | Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. | Cancer Manag Res | 2022 |
| 34633087 | Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. | Prostate | 2022 |
| 34294873 | Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 33126242 | Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. | JAMA Oncol | 2021 |
| 33826614 | Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. | PLoS One | 2021 |
| 33792945 | Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. | Prostate | 2021 |
| 33824031 | A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33872479 | Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. | Oncology (Williston Park) | 2021 |
| 33840525 | Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis. | Mayo Clin Proc | 2021 |
| 33798590 | Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. | Hum Pathol | 2021 |
| 34736604 | On the Road Back to Normalcy: Following Science Over Noise in SARS-CoV-2. | Mayo Clin Proc | 2021 |
| 34778690 | Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2021 |
| 34598946 | Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. | Clin Cancer Res | 2021 |
| 34101624 | FOXA1 overexpression suppresses interferon signaling and immune response in cancer. | J Clin Invest | 2021 |
| 34125579 | Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. | JCO Oncol Pract | 2021 |
| 34292336 | Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. | JAMA Netw Open | 2021 |
| 34354225 | A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. | NPJ Precis Oncol | 2021 |
| 33215787 | Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. | Oncologist | 2021 |
| 31567539 | Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. | Int J Gynecol Pathol | 2020 |
| 31787526 | Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. | Pancreatology | 2020 |
| 32086346 | Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. | Clin Cancer Res | 2020 |
| 32073512 | Genomic profiling proves metastasis of cutaneous melanoma to vitreal fluid. | Melanoma Res | 2020 |
| 31943289 | Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? | Prostate | 2020 |
| 33329980 | Evolving Natural History of Metastatic Prostate Cancer. | Cureus | 2020 |
| 32861340 | Targeting TMPRSS2 in SARS-CoV-2 Infection. | Mayo Clin Proc | 2020 |